CSL Limited Stock price

Equities

CSL

AU000000CSL8

Pharmaceuticals

Delayed Australian Stock Exchange 01:10:40 2023-10-02 am EDT Intraday chart for CSL Limited 5-day change 1st Jan Change
246.36 AUD -1.77% -2.62% -14.39%
Sales 2024 * 14,782 M 23,113 M Sales 2025 * 16,100 M 25,174 M Capitalization 78 178 M 122 B
Net income 2024 * 2,748 M 4,297 M Net income 2025 * 3,336 M 5,216 M EV / Sales 2024 *
5,93x
Net Debt 2024 * 9,459 M 14,790 M Net Debt 2025 * 7,780 M 12,164 M EV / Sales 2025 *
5,34x
P/E ratio 2024 *
28,6x
P/E ratio 2025 *
23,5x
Employees -
Yield 2024 *
1,64%
Yield 2025 *
1,86%
Free-Float99.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.77%
1 week-2.62%
Current month-1.77%
1 month-8.22%
3 months-10.82%
6 months-15.31%
Current year-14.39%
More quotes
1 week
246.36
Extreme 246.36
255.69
1 month
246.36
Extreme 246.36
271.65
Current year
246.36
Extreme 246.36
314.28
1 year
246.36
Extreme 246.36
314.28
3 years
240.10
Extreme 240.1
320.42
5 years
173.00
Extreme 173
342.75
10 years
63.77
Extreme 63.77
342.75
More quotes
Date Price Change Volume
23-10-02 246.36 -1.77% 546 082
23-09-29 250.80 -0.49% 925,453
23-09-28 252.04  0.00% 574,414
23-09-27 252.04 -1.39% 1,260,486
23-09-26 255.60 +1.03% 865,415

Delayed Quote Australian Stock Exchange, October 02, 2023 at 01:10 am EDT

More quotes
CSL Limited (CSL) is an Australia-based biotechnology company. The Company's areas of focus and exploration include rare and serious diseases, influenza vaccines, plasma collection, and therapies for iron deficiency and nephrology. The Company's segments include CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment manufactures, markets, and distributes plasma therapies (plasma products and recombinants). CSL Seqirus segment manufactures, markets, and distributes primarily influenza-related products and provides pandemic services to governments. The Company's CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency, dialysis and nephrology and rare diseases. The Company's geographical areas of operation include Australia, the United States of America, Germany, the United Kingdom, Switzerland, and China. CSL's products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.
Calendar
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
161.84USD
Average target price
210.18USD
Spread / Average Target
+29.87%
Consensus
  1. Markets
  2. Equities
  3. Stock CSL Limited - Australian Stock Exchange
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer